Related Experiment Videos
Treatment of scleroderma heart by D-penicillamine
British Heart Journal
|August 1, 1976
Insights
This case study shows D-penicillamine effectively treated cardiac issues in severe systemic sclerosis. The drug reduced heart size and improved patient symptoms, a novel finding for scleroderma heart disease.
Area of Science:
- Cardiology
- Rheumatology
- Pharmacology
Background:
- Systemic sclerosis is an autoimmune disease causing fibrosis and vascular abnormalities.
- Cardiac involvement, including cardiomegaly and heart failure, is a severe complication of systemic sclerosis.
- Limited treatment options exist for cardiac manifestations in systemic sclerosis.
Observation:
- A patient with severe diffuse systemic sclerosis presented with significant cardiomegaly and cardiac failure.
- The patient was treated with D-penicillamine, a chelating agent and immunomodulator.
- This represents the first reported use of D-penicillamine for scleroderma-associated heart disease.
Findings:
- D-penicillamine treatment led to a marked reduction in heart size.
- Clinical improvement in cardiac function and symptoms was observed.
- The patient experienced overall amelioration of systemic sclerosis complications.
Implications:
- D-penicillamine may be a viable therapeutic option for managing cardiac dysfunction in systemic sclerosis.
- Further research is warranted to confirm the efficacy and safety of D-penicillamine in scleroderma heart disease.
- This finding could expand treatment strategies for severe systemic sclerosis with cardiac involvement.
Abstract:
A case of severe diffuse systemic sclerosis with cardiomegaly and cardiac failure is described. Treatment with D-penicillamine caused a pronounced decrease in heart size, together with clinical improvement. The use of penicillamine in scleroderma heart has not previously been reported.